Molecular Subgroups of Endometrial Carcinoma in Romanian Patients

Evsei, Anca; Birceanu-Corobea, Adelina; Csonka, Tamas; Copca, Narcis; Sajin, Maria

doi:10.37358/rc.20.9.8337

Cited by 3 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been documented that increased TME induces PD-1/PD-L1 mediated fluctuating immune resistance, which usually leads to aggressive tumour phenotype and a poor prognosis. In our study, PD-L1 expression was highly correlated with this subgroup that additionally showed other unfavourable prognostic parameters: younger age, higher FIGO grade, deep myometrial invasion, tumour size, and positive LVSI 7 . Similar results were found in other studies 21 .…”

Section: Discussionsupporting

confidence: 60%

“…The samples of endometrial carcinomas were reviewed, cored (1 mm) in triplicate and arrayed as previously described 7 . Tissue microarray (TMA) sections were stained with antibodies against CD4 (Ventana, catalogue number 790-4423, clone SP35, Rabbit), CD8 (Ventana, catalogue number 790-4460, clone SP57, Rabbit), CD68 (Ventana, catalogue number 790-2931, clone KP-1, Mouse) and PD-L1 (Ventana, catalogue number 790-4907, clone SP263, Rabbit).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Tumour microenvironment and PD-L1 expression in endometrial carcinoma

Evsei

Birceanu-Corobea

Ghiţă

et al. 2021

Arch Balk Med Union

Self Cite

View full text Add to dashboard Cite

Le micro-environnement tumoral et l'expression de PD-L1 dans le carcinome endométrialIntroduction. L'immunothérapie est devenue une stratégie puissante dans le traitement du cancer avancé. Cela a généré de nouvelles recherches captivantes, concernant surtout le micro-environnement tumoral (TME), y compris le système de points de contrôle immunitaire, pour stratifier davantage les patients atteints de carcinome de l'endomètre (CE) et améliorer la thérapie ciblée. L'objectif de l'étude était d'évaluer l'impact du TME et du PD-L1 sur divers groupes moléculaires. Matériel et méthodes. 50 cas de CE précédemment diagnostiqués ont été testés pour CD4, CD8, CD68 et PD-L1. Résultats. Les tests PD-L1 dans notre groupe ont révélé 60% des cas présentant une positivité cellulaire <1%, 34% des cas présentant une positivité cellulaire de 1 à 49% et 6% des cas présentant une positivité cellulaire ≥ 50%. L'analyse statistique a révélé les corrélations significatives suivantes avec les paramètres ABSTRACT Introduction. Immunotherapy has emerged as a potent strategy for treating advanced cancer. This generated new and exciting research, especially regarding tumour microenvironment (TME), including the immune checkpoint system, to further stratify endometrial carcinoma (EC) patients and improve targeted therapy.The objective of the study was to evaluate the TME and PD-L1 impact on various molecular groups. Material and methods. 50 cases of formerly diagnosed ECs were tested for CD4, CD8, CD68 and PD-L1. Results. PD-L1 testing in our group revealed 60% of cases showing <1% cell positivity, 34% of cases showing 1-49% cell positivity, and 6% of cases showing ≥50% cell positivity. The statistical analysis revealed the following significant correlations with clinical and pathological parameters: pT (p=0.012), FIGO stage (p=0.028), myometrial invasion (p=0.037) and ESMO risk stratification (p=0.017). PD-L1 expression in the three different molecular subgroups showed significant correlation with the MSI-H subgroup (p=0.014). The

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Methodsmentioning

confidence: 99%

Tumour microenvironment and PD-L1 expression in endometrial carcinoma

Evsei

Birceanu-Corobea

Ghiţă

et al. 2021

Arch Balk Med Union

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cases selection was performed from a previous database 7 and included 50 cases of ECs from the Pathology Department archives, diagnosed between 2014 and 2019. Molecular classification for ECs was already performed and divided the cohort into four subgroups: MSS subgroup, MSI subgroup, p53abn subgroup and p53wt subgroup 7 . In addition, Programmed Death -Ligand 1 (PD-L1) testing was assessed on this cohort 8 .…”

Section: Methodsmentioning

confidence: 99%

“…The obtained samples of endometrial carcinoma were reviewed, cored (1mm) in triplicate and arrayed as previously described 7 . Tissue sections were stained with antibodies against -catenin (Ventana, catalogue number 760-4242, clone 14, Mouse) and protocol was followed for staining.…”

Section: Methodsmentioning

confidence: 99%

Βeta-catenin – an important immunohistochemical tool in stratifying endometrial carcinomas?

Evsei¹,

Birceanu-Corobea²,

Ghiţă³

et al. 2021

Arch Balk Med Union

Self Cite

View full text Add to dashboard Cite

La bêta-caténine -un outil immunohistochimique important dans la stratification des carcinomes endométriaux?Introduction. Des recherches récentes ont montré que l'expression de la -caténine nucléaire immunohistochimique est un substitut valide pour la mutation de l'exon 3 CTNBB1 dans les carcinomes de l'endomètre (CE). Cette mutation est un facteur pronostique indépendant et identifie un sous-groupe de carcinomes de l'endomètre à bas degré qui ont une tendance à la récidive et à un pronostic défavorable. L'objectif de l'étude était d'évaluer l'expression de la -caténine nucléaire dans différents sous-groupes moléculaires de CE. Matériel et méthodes. Nous avons testé l'expression immunohistochimique de la -caténine nucléaire dans 50 cas de carcinomes de l'endomètre diagnostiqués dans deux unités cliniques. Une analyse statistique a ABSTRACTIntroduction. Recent research has demonstrated that the immunohistochemical nuclear -catenin expression is a valid surrogate for CTNNB1 exon 3 mutation in endometrial carcinomas (ECs). This mutation is an independent prognostic factor which identifies a subgroup of low-grade endometrial carcinomas that have a tendency for recurrence and worse prognosis. The objective of the study was to evaluate nuclear -catenin expression in different molecular subgroups of E Cs. Material and methods. We tested immunohistochemical nuclear -catenin expression in 50 cases of endometrial carcinomas diagnosed in two clinical institutions. Statistical analysis was performed between -catenin expression and various clinical, demographic, pathological and immunohistochemical parameters (age, myometrial invasion, FIGO grade, histopathological subtype, hormone receptors -ER, PR etc). Additionally, we analysed what molecular subgroup

show abstract

Association of molecular subgroups with pathological parameters in endometrial carcinomas

Ratnakaran,

Nair,

Rajanbabu

et al. 2023

Indian Journal of Cancer

View full text Add to dashboard Cite

Background: The integration of molecular features into the already existing pathological classification of endometrial carcinomas will offer significant prognostic information. As the literature search reveals, there are no studies from India that have classified these carcinomas based on molecular subtypes. The aim of the study was to classify endometrial carcinomas into four subtypes based on their molecular and immunohistochemical features and to find out the association of each of these molecular subtypes with the other pathological parameters. Methods: A prospective study was done on 37 consecutive cases of fresh hysterectomy specimens, biopsy-proven as endometrial carcinomas between November 2019 and August 2020. Three immunohistochemical markers (p53, mismatch repair proteins,MutS homolog6 and Postmeiotic seggregation 2 respectively[MSH6, and PMS2]), along with DNA (deoxyribonucleic acid) sequencing of selected regions of the POLE gene was performed in each of the 37 cases. Endometrial carcinomas were subclassified into four subtypes, and the association of each of these four subtypes with the other pathological parameters was also explored. Statistical analysis was done using the IBM Statistical Package for the Social Science (SPSS) Version 20.0 software (IBM SPSS, USA). Results: Among the 37 cases studied, eight (21.6%) cases were p53 abnormal, eight (21.6%) cases showed MMR-D (mismatch repair deficient), one case (2.7%) showed mutation of POLE, and 21 cases (56.8%) were assembled under p53 wild-type. Higher grade endometrial carcinomas showed more (80.0%) p53 abnormal (P < 0.001). All the p53 wild-type (100%) were of Type 1 endometrial carcinoma subtype (P = 0.001) and low-grade type (90.5%; P = 0.005). Conclusion: Our study confirms that the type of carcinoma and grade correlates with p53 expression, p53 abnormal being associated with higher grade and type 2 endometrial carcinomas, whereas p53 wild-type is associated with low-grade and type 1 endometrial carcinoma. There was only one case of the POLE subtype identifiable in our study.

show abstract

Molecular Subgroups of Endometrial Carcinoma in Romanian Patients

Cited by 3 publications

References 16 publications

Tumour microenvironment and PD-L1 expression in endometrial carcinoma

Tumour microenvironment and PD-L1 expression in endometrial carcinoma

Βeta-catenin – an important immunohistochemical tool in stratifying endometrial carcinomas?

Association of molecular subgroups with pathological parameters in endometrial carcinomas

Contact Info

Product

Resources

About